CN1331478C - Pearl eye drops for improving eyesight and preparation method thereof - Google Patents
Pearl eye drops for improving eyesight and preparation method thereof Download PDFInfo
- Publication number
- CN1331478C CN1331478C CNB2004100670137A CN200410067013A CN1331478C CN 1331478 C CN1331478 C CN 1331478C CN B2004100670137 A CNB2004100670137 A CN B2004100670137A CN 200410067013 A CN200410067013 A CN 200410067013A CN 1331478 C CN1331478 C CN 1331478C
- Authority
- CN
- China
- Prior art keywords
- margarita liquid
- mingmu diyanye
- zhenzhu mingmu
- water
- margarita
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 239000003889 eye drop Substances 0.000 title abstract description 5
- 230000004438 eyesight Effects 0.000 title abstract 3
- 229940012356 eye drops Drugs 0.000 title abstract 2
- 239000002562 thickening agent Substances 0.000 claims abstract description 21
- 239000007788 liquid Substances 0.000 claims description 59
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 58
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 58
- 235000005956 Cosmos caudatus Nutrition 0.000 claims description 56
- 244000293323 Cosmos caudatus Species 0.000 claims description 56
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 44
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 29
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 29
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 29
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 29
- 239000011780 sodium chloride Substances 0.000 claims description 29
- 239000000243 solution Substances 0.000 claims description 28
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 27
- 239000008215 water for injection Substances 0.000 claims description 20
- 238000003756 stirring Methods 0.000 claims description 13
- 239000012153 distilled water Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 238000009413 insulation Methods 0.000 claims description 3
- 238000005374 membrane filtration Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 21
- 210000001508 eye Anatomy 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 7
- 230000000638 stimulation Effects 0.000 abstract description 5
- 206010010741 Conjunctivitis Diseases 0.000 abstract description 2
- 208000003464 asthenopia Diseases 0.000 abstract description 2
- 201000005547 chronic conjunctivitis Diseases 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 229940079593 drug Drugs 0.000 description 9
- 210000004087 cornea Anatomy 0.000 description 8
- 206010023683 lagophthalmos Diseases 0.000 description 8
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 5
- 229960001631 carbomer Drugs 0.000 description 5
- 238000013401 experimental design Methods 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- -1 HA) Chemical compound 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 229940020947 fluorescein sodium Drugs 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to pearl eyesight improving eye drops for symptoms such as asthenopia, chronic conjunctivitis and the like, in particular to a pearl eyesight improving eye drop preparation and a preparation method thereof. The thickening agent is added in the prescription of the preparation, so that the retention time of the medicine in eyes can be increased, the stimulation effect is reduced, and the aim of improving the curative effect of the medicine on the premise that the production condition and equipment do not need to be changed is fulfilled.
Description
(1) technical field
The present invention relates to a kind of ZHENZHU MINGMU DIYANYE and preparation method thereof.
(2) background technology
ZHENZHU MINGMU DIYANYE has clearing away heat-fire, and the effect of nourishing the liver to improve visual acuity, antiinflammatory is mainly used in symptoms such as asthenopia and chronic conjunctivitis, also is used to improve ophthalmic bloated, ophthalmic pruritus.But according to present common prescription, can find that most of ZHENZHU MINGMU DIYANYE is run off after use, medicine within the eye the time of staying shorter.
(3) summary of the invention
The purpose of this invention is to provide a kind of ZHENZHU MINGMU DIYANYE (the main constituent Margarita liquid comprises the Margarita in various sources), be equipped with thickening agent, make a kind of can increase medicine within the eye the time of staying and reduce the new ZHENZHU MINGMU DIYANYE (colloid solution) of stimulation.
Another object of the present invention provides a kind of preparation method of ZHENZHU MINGMU DIYANYE.
For reaching the goal of the invention the technical solution adopted in the present invention be:
ZHENZHU MINGMU DIYANYE is equipped with following component and forms: Margarita liquid, Borneolum Syntheticum, ethyl hydroxybenzoate, thickening agent, sodium chloride, ethanol, water for injection.
Above Margarita liquid is the extracting solution of Margarita powder, usually make with following method: take by weighing Margarita powder and add in the water for injection of its 4 times of weight, heat to 95～100 ℃, insulation makes abundant reaction 2～3 hours, inclining supernatant, makes Margarita liquid through 0.45 μ m membrane filtration then, and described Margarita liquid total protein content is greater than 200 μ g/ml, usually the Margarita liquid total protein content is controlled at 200 μ g/ml～500 μ g/ml, and preferably the Margarita liquid total protein content is greater than 300 μ g/ml.
Thickening agent in the above-mentioned prescription is main contribution of the present invention, and the adding of thickening agent can make the viscosity of eye drop increase, and increases the medicine time of staying within the eye, thereby increases the effect of medicine, because the increase of viscosity also can reduce stimulation, increases drug effect simultaneously.Thickening agent can be one or several combination of following formula: and hyaluronic acid sodium (hyaluronate sodium, HA), methylcellulose, carbomer (Carbomer), hydroxypropyl emthylcellulose, sodium carboxymethyl cellulose.Wherein use the hyaluronic acid sodium better effects if.
ZHENZHU MINGMU DIYANYE of the present invention is taked following prescription:
Margarita liquid 20ml (contain total protein concentration and be no less than 20mg)
Borneolum Syntheticum 0.5g-1.5g
Ethyl hydroxybenzoate 0.3g-0.8g
Thickening agent 1.0g-4.0g
Sodium chloride 5.0g-10.0g
95% ethanol 3ml-6ml
Water for injection adds to 1000ml
ZHENZHU MINGMU DIYANYE of the present invention, more preferably prescription consists of:
Margarita liquid 20ml (contain total protein concentration and be no less than 20mg)
Borneolum Syntheticum 0.5g-1.5g
Ethyl hydroxybenzoate 0.3g-0.8g
Hyaluronic acid sodium 1.0g-4.0g
Sodium chloride 5.0g-10.0g
95% ethanol 3ml-6ml
Water for injection adds to 1000ml
Preferred prescription is:
Margarita liquid 20ml (contain total protein concentration and be no less than 20mg)
Borneolum Syntheticum 1.0g
Ethyl hydroxybenzoate 0.5g
Hyaluronic acid sodium 1.5g
Sodium chloride 8.9g
95% ethanol 5ml
Water for injection adds to 1000ml
Above-mentioned ZHENZHU MINGMU DIYANYE can make by following step:
A. sodium chloride is added in an amount of distilled water, heated and boiled is cooled to 80 degrees centigrade and adds Margarita liquid, and the limit edged is cooled to 60 degrees centigrade;
B. Borneolum Syntheticum, ethyl hydroxybenzoate are dissolved in the ethanol, are added dropwise to while stirring in the above solution, add water and stirred 30-50 minute;
C. the thickening agent hyaluronic acid sodium is added in the above-mentioned solution, it is dissolved fully, regulate pH to 5.5-7.5, filter, record into 1000ml, embedding, promptly.
PH value in the above-mentioned c step is more excellent to be 6.5.
The beneficial effect of ZHENZHU MINGMU DIYANYE of the present invention is mainly reflected in: added thickening agent in the ZHENZHU MINGMU DIYANYE prescription viscosity of eye drop is increased, increase the medicine time of staying within the eye, thereby increase the effect of medicine, because the increase of viscosity also can reduce stimulation, increase drug effect simultaneously.Particularly selecting hyaluronic acid sodium for use is thickening agent, makes that the ZHENZHU MINGMU DIYANYE result of use is better.
(4) specific embodiment
Embodiment 1: ZHENZHU MINGMU DIYANYE and preparation thereof
Prescription
Margarita liquid 20ml (contain total protein concentration and be no less than 20mg)
Borneolum Syntheticum 1.0g
Ethyl hydroxybenzoate 0.5g
Hyaluronic acid sodium 1.5g
Sodium chloride 8.9g
95% ethanol 5ml
Water for injection adds to 1000ml;
Preparation process:
The preparation of Margarita liquid: take by weighing Margarita powder 500g and add in the water for injection of 2000ml, heat, insulation to 95～100 ℃, stirring makes abundant reaction 2～3 hours, inclining supernatant, and supernatant makes Margarita liquid through 0.45 μ m membrane filtration, and measuring described Margarita liquid total protein content is 300 μ g/ml.
The preparation of ZHENZHU MINGMU DIYANYE:
(1) sodium chloride is added in an amount of distilled water, heated and boiled is cooled to 80 degrees centigrade and adds Margarita liquid, and the limit edged is cooled to 60 degrees centigrade;
(2) Borneolum Syntheticum, ethyl hydroxybenzoate are dissolved in the ethanol, are added dropwise to while stirring in the above solution, add water and stirred 50 minutes;
(3) the thickening agent hyaluronic acid sodium is added in the above-mentioned solution, it is dissolved fully, regulate pH to 6.5, filter, record into 1000ml, embedding, promptly.
Embodiment 2: ZHENZHU MINGMU DIYANYE and preparation thereof
Prescription:
Margarita liquid 20ml
Borneolum Syntheticum 1.0g
Ethyl hydroxybenzoate 0.5g
Hyaluronic acid sodium 1.0g
Sodium chloride 5.5g
95% ethanol 5ml
Water for injection adds to 1000ml;
Preparation process:
Get the Margarita liquid that embodiment 1 makes.
(1) sodium chloride is added in an amount of distilled water, heated and boiled is cooled to 80 degrees centigrade and adds Margarita liquid, and the limit edged is cooled to 60 degrees centigrade;
(2) Borneolum Syntheticum, ethyl hydroxybenzoate are dissolved in the ethanol, are added dropwise to while stirring in the above solution, add water and stirred 40 minutes;
(2) the thickening agent hyaluronic acid sodium is added in the above-mentioned solution, it is dissolved fully, regulate pH to 6.0, filter, record into 1000ml, embedding, promptly.
Embodiment 3: ZHENZHU MINGMU DIYANYE
Prescription:
Margarita liquid 20ml (contain total protein concentration and be no less than 20mg)
Borneolum Syntheticum 1.0g
Ethyl hydroxybenzoate 0.5g
Hyaluronic acid sodium 1.2g
Sodium chloride 6.5g
95% ethanol 5ml
Water for injection adds to 1000ml
Preparation process:
Get the Margarita liquid that embodiment 1 makes.
(1) sodium chloride is added in an amount of distilled water, heated and boiled is cooled to 80 degrees centigrade and adds Margarita liquid, and the limit edged is cooled to 60 degrees centigrade;
(2) Borneolum Syntheticum, ethyl hydroxybenzoate are dissolved in the ethanol, are added dropwise to while stirring in the above solution, add water and stirred 50 minutes;
(3) the thickening agent hyaluronic acid sodium is added in the above-mentioned solution, it is dissolved fully, regulate pH to 7.5, filter, record into 1000ml, embedding, promptly.
Embodiment 4: ZHENZHU MINGMU DIYANYE and preparation thereof
Prescription:
Margarita liquid 20ml (contain total protein concentration and be no less than 20mg)
Borneolum Syntheticum 1.0g
Ethyl hydroxybenzoate 0.5g
Hyaluronic acid sodium 1.5g
Sodium chloride 7.5g
95% ethanol 5ml
Water for injection adds to 1000ml;
Preparation process:
Get the Margarita liquid that embodiment 1 makes.
(1) sodium chloride is added in an amount of distilled water, heated and boiled is cooled to 80 degrees centigrade and adds Margarita liquid, and the limit edged is cooled to 60 degrees centigrade;
(2) Borneolum Syntheticum, ethyl hydroxybenzoate are dissolved in the ethanol, are added dropwise to while stirring in the above solution, add water and stirred 30 minutes;
(3) the thickening agent hyaluronic acid sodium is added in the above-mentioned solution, it is dissolved fully, regulate pH to 6.0, filter, record into 1000ml, embedding, promptly.
Embodiment 5: ZHENZHU MINGMU DIYANYE
Prescription:
Margarita liquid 20ml (contain total protein concentration and be no less than 20mg)
Borneolum Syntheticum 1.0g
Ethyl hydroxybenzoate 0.5g
Hyaluronic acid sodium 1.5g
Sodium chloride 8.5g
95% ethanol 5ml
Water for injection adds to 1000ml;
Preparation process:
Get the Margarita liquid that embodiment 1 makes.
(1) sodium chloride is added in an amount of distilled water, heated and boiled is cooled to 80 degrees centigrade and adds Margarita liquid, and the limit edged is cooled to 60 degrees centigrade;
(2) Borneolum Syntheticum, ethyl hydroxybenzoate are dissolved in the ethanol, are added dropwise to while stirring in the above solution, add water and stirred 30 minutes;
(3) the thickening agent hyaluronic acid sodium is added in the above-mentioned solution, it is dissolved fully, regulate pH to 5.5, filter, record into 1000ml, embedding, promptly.
Embodiment 6: ZHENZHU MINGMU DIYANYE and preparation thereof
Prescription:
Margarita liquid 20ml (contain total protein concentration and be no less than 20mg)
Borneolum Syntheticum 1.0g
Ethyl hydroxybenzoate 0.5g
Hyaluronic acid sodium 2.7g
Sodium chloride 9.5g
95% ethanol 5ml
Water for injection adds to 1000ml;
Preparation process:
Get the Margarita liquid that embodiment 1 makes.
(1) sodium chloride is added in an amount of distilled water, heated and boiled is cooled to 80 degrees centigrade and adds Margarita liquid, and the limit edged is cooled to 60 degrees centigrade;
(2) Borneolum Syntheticum, ethyl hydroxybenzoate are dissolved in the ethanol, are added dropwise to while stirring in the above solution, add water and stirred 30 minutes;
(3) the thickening agent hyaluronic acid sodium is added in the above-mentioned solution, it is dissolved fully, regulate pH to 7.5, filter, record into 1000ml, embedding, promptly.
Embodiment 7: ZHENZHU MINGMU DIYANYE and preparation thereof
Prescription:
Margarita liquid 20ml (contain total protein concentration and be no less than 20mg)
Borneolum Syntheticum 1.0g
Ethyl hydroxybenzoate 0.5g
Hyaluronic acid sodium 2.5g
Sodium chloride 10.0g
95% ethanol 5ml
Water for injection adds to 1000ml;
Preparation process:
Get the Margarita liquid that embodiment 1 makes.
(1) sodium chloride is added in an amount of distilled water, heated and boiled is cooled to 80 degrees centigrade and adds Margarita liquid, and the limit edged is cooled to 60 degrees centigrade;
(2) Borneolum Syntheticum, ethyl hydroxybenzoate are dissolved in the ethanol, are added dropwise to while stirring in the above solution, add water and stirred 50 minutes;
(3) the thickening agent hyaluronic acid sodium is added in the above-mentioned solution, it is dissolved fully, regulate pH to 7.5, filter, record into 1000ml, embedding, promptly.
Embodiment 8: ZHENZHU MINGMU DIYANYE and preparation thereof
Prescription:
Margarita liquid 20ml (contain total protein concentration and be no less than 20mg)
Borneolum Syntheticum 1.0g
Ethyl hydroxybenzoate 0.5g
Hyaluronic acid sodium 1.8g
Sodium chloride 5.5g
95% ethanol 5ml
Water for injection adds to 1000ml;
Preparation process:
Get the Margarita liquid that embodiment 1 makes.
(1) sodium chloride is added in an amount of distilled water, heated and boiled is cooled to 80 degrees centigrade and adds Margarita liquid, and the limit edged is cooled to 60 degrees centigrade;
(2) Borneolum Syntheticum, ethyl hydroxybenzoate are dissolved in the ethanol, are added dropwise to while stirring in the above solution, add water and stirred 30 minutes;
(3) the thickening agent hyaluronic acid sodium is added in the above-mentioned solution, it is dissolved fully, regulate pH to 7.0, filter, record into 1000ml, embedding, promptly.
Embodiment 9: ZHENZHU MINGMU DIYANYE
Prescription:
Margarita liquid 20ml (contain total protein concentration and be no less than 20mg)
Borneolum Syntheticum 1.0g
Ethyl hydroxybenzoate 0.5g
Carbomer 2.0g
Sodium chloride 5.5g
95% ethanol 5ml
Water for injection adds to 1000ml;
Preparation process:
Get the Margarita liquid that embodiment 1 makes.
(1) sodium chloride is added in an amount of distilled water, heated and boiled is cooled to 80 degrees centigrade and adds Margarita liquid, and the limit edged is cooled to 60 degrees centigrade;
(2) Borneolum Syntheticum, ethyl hydroxybenzoate are dissolved in the ethanol, are added dropwise to while stirring in the above solution, add water and stirred 40 minutes;
(3) the thickening agent carbomer is added in the above-mentioned solution, it is dissolved fully, regulate pH to 6.5, filter, record into 1000ml, embedding, promptly.
Embodiment 10: ZHENZHU MINGMU DIYANYE
Prescription:
Margarita liquid 20ml (contain total protein concentration and be no less than 20mg)
Borneolum Syntheticum 1.0g
Ethyl hydroxybenzoate 0.5g
Methylcellulose 1.8g
Sodium chloride 5.5g
95% ethanol 5ml
Water for injection adds to 1000ml;
Preparation process:
Get the Margarita liquid that embodiment 1 makes.
(1) sodium chloride is added in an amount of distilled water, heated and boiled is cooled to 80 degrees centigrade and adds Margarita liquid, and the limit edged is cooled to 60 degrees centigrade;
(2) Borneolum Syntheticum, ethyl hydroxybenzoate are dissolved in the ethanol, are added dropwise to while stirring in the above solution, add water and stirred 30 minutes;
(3) the thickening agent methylcellulose is added in the above-mentioned solution, it is dissolved fully, regulate pH to 5.5, filter, record into 1000ml, embedding, promptly.
Embodiment 11: the test of ZHENZHU MINGMU DIYANYE cornea retentivity
Get ZHENZHU MINGMU DIYANYE (getting embodiment 1 gained sample), with common ZHENZHU MINGMU DIYANYE is reference substance, regulate pH and osmotic pressure, be prepared into colloid solution, the examination appearance character, measure each sample viscosity with the NDJ-1 rotational viscometer, and adopt dynamic monitoring fluorescent marker method to measure product, adopt the situation of sprawling (more little being easy to more of contact angle sprawled) of measuring contact horn cupping examination sample in the holdup time of rabbit cornea.
Dynamic monitoring fluorescent marker method is measured product in the holdup time of rabbit cornea test method: add biological dye's fluorescein sodium of 2% in above-mentioned each sample, thing serves as a mark.Choose 7 healthy adult white rabbit, its palpebra inferior is drawn back from eyeball gently, get and tried thing 0.1ml and splash in the conjunctival sac, catacleisis is 10 seconds up and down, observing fluorescein sodium extinction time on the rabbit cornea under the 254nm uviol lamp, with rabbit eyes meansigma methods as the holdup time of sample at cornea.Result of the test sees Table 1
Table 1 rabbit corneal retentivity result of the test
| Sample | Appearance character | Viscosity (mPa.s) | The cornea holdup time (minute) | Contact angle | |
| Common ZHENZHU MINGMU DIYANYE | Clear liquid | 4 | 60.5 | 22 | |
| Embodiment 1 | Clear liquid | 110 | 80 | 25 | |
| Clear liquid | 370 | 105 | 30 | ||
| HPMC | 0.5％ | Clear liquid | 41 | 70 | 46 |
| 1.0％ | Clear liquid | 183 | 72.5 | 54 | |
| Carbomer | 0.2％ | Clear and bright thick liquid | 3533 | 90 | 68 |
| 0.3％ | Transparent semisolid | 11867 | 115 | 82 | |
Above result of the test shows: the ZHENZHU MINGMU DIYANYE of the embodiment of the invention 1 is compared with common ZHENZHU MINGMU DIYANYE, has cornea retentivity preferably, therefore and viscosity and surface spreading performance are also better, have improved curative effect of medication under the prerequisite that working condition and equipment need not change and have also reduced stimulation.
Embodiment 12: lagophthalmos tear determination of drug concentration
1) test objective: this test is contrast with the sample and the common ZHENZHU MINGMU DIYANYE of inventive embodiments 1, has carried out single dose pharmacokinetics and drug release characteristic comparison in the rabbit tear liquid.
2) EXPERIMENTAL DESIGN
A. animal is selected
Select 2 of adult healthy rabbit, a female hero, body weight 2.5-3.0Kg, the experimental animal quality certification number: saxk (Shanghai) 2002-0008.
B. test method
4 eyes of 2 adult healthy rabbit adopt the own control EXPERIMENTAL DESIGN, and the period 1,4 eyes gave the sample of the embodiment of the invention 1, gave common ZHENZHU MINGMU DIYANYE second round.
Medication: rabbit is placed in the securing loop, draw same sample 50ul with corrected micropipettor, the rabbit palpebra inferior outwards drawn back gently make into a pouch shape, medicinal liquid is splashed into wherein, then palpebra inferior is resetted and cover on the cornea gently, so drawing back a covering This move repeated four times in 5 seconds, so that medicine is fully mixed with tear, draw tear respectively at the appointed time, measure tear Chinese medicine content (carrying out a time point test every day), and be converted into the tear drug level; Before the administration in second day, draw the lagophthalmos tear with filter paper equally, measure tear Chinese medicine content, go into to detect medicine, can carry out the administration second time, the same operation.Period 1 is dripped same sample, by the EXPERIMENTAL DESIGN point in time sampling, got have a few after, in rabbit one week of interval, carry out second round with method.
Sample time: sampling in 0,5,10,20,30,45,60,120,180,240,360,480 minute before administration and after the administration.
Sampling method: draw lagophthalmos tear (30 seconds absorption time) with quantitative filter paper, put into tool plug plastics tubule after weighing, it is standby to put in the refrigerator (18 ℃).
3) result of the test
The concentration of ZHENZHU MINGMUYE in the tear behind 4 eye single doses of 2 adult healthy rabbit dosing eyes that adopted rp-hplc determination, wherein blood drug level-time data see Table 2 respectively, table 3.
The lagophthalmos tear drug level (mg/ml) of table 2. embodiment 1 sample different time
| Being tried lagophthalmos numbers | Time (branch) | ||||||||||
| 5 | 10 | 20 | 30 | 45 | 60 | 120 | 180 | 240 | 360 | 480 | |
| A | 1.749 | 2.001 | 1.252 | 0.915 | 0.654 | 0.315 | 0.087 | 0.076 | 0.041 | 0.01 | 0 |
| B | 1.491 | 1.725 | 1.012 | 0.856 | 0.545 | 0.436 | 0.103 | 0.049 | 0.029 | 0.011 | 0 |
| C | 1.526 | 1.897 | 0.975 | 0.844 | 0.461 | 0.414 | 0.103 | 0.089 | 0.063 | 0.017 | 0 |
| D | 1.878 | 1.912 | 1.353 | 1.025 | 0.668 | 0.525 | 0.099 | 0.054 | 0.025 | 0 | 0 |
| X | 1.66 | 1.88 | 1.15 | 0.91 | 0.58 | 0.42 | 0.10 | 0.067 | 0.054 | 0.0095 | 0 |
| SD | 0.17 | 0.23 | 0.17 | 0.079 | 0.097 | 0.079 | 0.0089 | 0.015 | 0.016 | 0.007 | 0 |
The lagophthalmos tear drug level (mg/ml) of the common ZHENZHU MINGMU DIYANYE different time of table 3.
| Being tried lagophthalmos numbers | Time (branch) | ||||||||||
| 5 | 10 | 20 | 30 | 45 | 60 | 120 | 180 | 240 | 360 | 480 | |
| A | 2.687 | 1.353 | 0.946 | 0.464 | 0.147 | 0.1031 | 0.05 | 0.024 | 0.0129 | 0.008 | 0 |
| B | 2.128 | 1.235 | 0.766 | 0.385 | 0.1794 | 0.0987 | 0.044 | 0.01 | 0.008 | 0 | 0 |
| C | 1.982 | 1.532 | 0.853 | 0.562 | 0.2031 | 0.1137 | 0.061 | 0.0307 | 0.0112 | 0 | 0 |
| D | 2.453 | 1.946 | 0.714 | 0.369 | 0.1045 | 0.07351 | 0.023 | 0.012 | 0.0075 | 0 | 0 |
| X | 2.31 | 1.52 | 0.8 | 0.45 | 0.16 | 0.079 | 0.045 | 0.02 | 0.010 | 0.002 | 0 |
| SD | 0.289 | 0.304 | 0.108 | 0.07 | 0.046 | 0.022 | 0.019 | 0.013 | 0.0053 | 0.0046 | 0 |
4) test brief summary
Result of the test shows: after 4 eyes of 2 rabbit give the 50ul embodiment of the invention 1 sample and common ZHENZHU MINGMU DIYANYE respectively, each time period lagophthalmos tear drug level the former apparently higher than the latter, show that embodiment 1 sample obviously is better than common ZHENZHU MINGMU DIYANYE.
Claims (6)
1. ZHENZHU MINGMU DIYANYE, the prescription that it is characterized in that described ZHENZHU MINGMU DIYANYE is that every 1000ml specifically consists of:
Margarita liquid 20ml,
Borneolum Syntheticum 0.5g-1.5g,
Ethyl hydroxybenzoate 0.3g-0.8g,
Hyaluronic acid sodium 1.0g-4.0g,
Sodium chloride 5.0g-10.0g,
95% ethanol 3ml-6ml,
Surplus is a water for injection.
2. ZHENZHU MINGMU DIYANYE as claimed in claim 1, it is characterized in that described Margarita liquid is to take by weighing Margarita powder to add in the water for injection of its 4 times of weight, heat to 95～100 ℃, insulation makes abundant reaction 2～3 hours, incline and supernatant, make Margarita liquid through 0.45 μ m membrane filtration then, described Margarita liquid total protein content is greater than 200 μ g/ml.
3. ZHENZHU MINGMU DIYANYE as claimed in claim 2 is characterized in that described Margarita liquid total protein content is 200 μ g/ml～500 μ g/ml.
4. ZHENZHU MINGMU DIYANYE as claimed in claim 1, the prescription that it is characterized in that described ZHENZHU MINGMU DIYANYE are that every 1000ml consists of:
Margarita liquid 20ml,
Borneolum Syntheticum 1.0g,
Ethyl hydroxybenzoate 0.5g,
Hyaluronic acid sodium 1.5g,
Sodium chloride 8.9g,
95% ethanol 5ml,
Surplus is a water for injection.
5. method for preparing as the described ZHENZHU MINGMU DIYANYE of one of claim 1～3, the prescription that it is characterized in that described ZHENZHU MINGMU DIYANYE is that every 1000ml consists of:
Margarita liquid 20ml,
Borneolum Syntheticum 0.5g-1.5g,
Ethyl hydroxybenzoate 0.3g-0.8g,
Hyaluronic acid sodium 1.0g-4.0g,
Sodium chloride 5.0g-10.0g,
95% ethanol 3ml-6ml,
Surplus is a water for injection;
And adopt following steps to prepare:
A. sodium chloride is added in an amount of distilled water, heated and boiled is cooled to 80 ℃ and adds Margarita liquid, and the limit edged is cooled to 60 ℃;
B. Borneolum Syntheticum, ethyl hydroxybenzoate are dissolved in the ethanol, are added dropwise to while stirring in the above solution, add water and stirred 30-50 minute;
C. the thickening agent hyaluronic acid sodium is added in the above-mentioned solution, it is dissolved fully, regulate pH to 5.5-7.5, filter, record into 1000ml, embedding, promptly.
6. ZHENZHU MINGMU DIYANYE preparation method as claimed in claim 5 is characterized in that described pH value is 6.5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100670137A CN1331478C (en) | 2004-09-28 | 2004-09-28 | Pearl eye drops for improving eyesight and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100670137A CN1331478C (en) | 2004-09-28 | 2004-09-28 | Pearl eye drops for improving eyesight and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1634149A CN1634149A (en) | 2005-07-06 |
| CN1331478C true CN1331478C (en) | 2007-08-15 |
Family
ID=34846625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100670137A Expired - Lifetime CN1331478C (en) | 2004-09-28 | 2004-09-28 | Pearl eye drops for improving eyesight and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1331478C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100453086C (en) * | 2006-06-22 | 2009-01-21 | 武汉远大制药集团有限公司 | Gel for removing ocular by ice pearl and its preparation |
| CN102526112B (en) * | 2012-02-20 | 2013-10-30 | 苏州工业园区天龙制药有限公司 | Sustained-release pearl clear-sighted eye drops and preparation method thereof |
| CN103623003B (en) * | 2013-09-09 | 2016-03-23 | 苏州工业园区天龙制药有限公司 | A kind of ZHENZHU MINGMU DIYANYE and preparation method thereof |
| CN105769920A (en) * | 2014-12-25 | 2016-07-20 | 苏州太湖美药业有限公司 | Pearl clear-sighted eye drops and preparation method |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1416824A (en) * | 2002-11-12 | 2003-05-14 | 武汉天天明药业有限责任公司 | Medicament for preventing and treating myopia and asthenopia |
-
2004
- 2004-09-28 CN CNB2004100670137A patent/CN1331478C/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1416824A (en) * | 2002-11-12 | 2003-05-14 | 武汉天天明药业有限责任公司 | Medicament for preventing and treating myopia and asthenopia |
Non-Patent Citations (3)
| Title |
|---|
| 一种新型增稠剂应用于氯霉素滴眼液时药物的稳定性研究 黄虹，唐琦文，上海医药，第20卷第4期 1999 * |
| 一种新型增稠剂应用于氯霉素滴眼液时药物的稳定性研究 黄虹，唐琦文，上海医药，第20卷第4期 1999;部颁标准中药成方制剂第17册 卫生部药典委员会，189，卫生部药典委员会 1998 * |
| 部颁标准中药成方制剂第17册 卫生部药典委员会，189，卫生部药典委员会 1998 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1634149A (en) | 2005-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102100693A (en) | Artificial tears including carnosine and preparation method thereof | |
| CN102140079B (en) | Novel yunaconitine and preparation method thereof as well as pharmaceutical composition based on compound as active ingredient and application of novel yunaconitine | |
| CN104688672B (en) | Puerarin gel eyedrop is preparing the application in treating retinopathy medicine | |
| CN1331478C (en) | Pearl eye drops for improving eyesight and preparation method thereof | |
| CN106619573B (en) | Timolol maleate cubic liquid crystal nano eyedrop and preparation method thereof | |
| CN111870610B (en) | Application of luteolin-7-O-glucoside in preparation of medicine for treating diseases caused by retinal degeneration | |
| CN101455628B (en) | Preparation method of gel composition for eyes | |
| CN102512467A (en) | Ophthalmic preparation of panax notoginseng saponins and preparation method thereof | |
| CN101703503B (en) | Application of organic dicarboxylic acid salts in preparing medicaments for preventing and treating cataract | |
| CN100563628C (en) | A kind of Bendalysine eye gel preparation and preparation method thereof | |
| CN103720641A (en) | Taurine-containing ophthalmic in-vivo gel preparation and preparation method thereof | |
| CN1985801A (en) | Benzydalysine eye drop and its preparing method | |
| CN104546692B (en) | BFGF bovine basic fibroblast growth factor gel for eye use | |
| CN104622800A (en) | Bendazac lysine eye drop and preparation method thereof | |
| CN1830462B (en) | Erycibes extraction, medicinal composition containing said oxtraction and its preparation method | |
| CN101632717A (en) | In situ forming eye gel preparation for treating myopia and asthenopia and preparation method thereof | |
| CN109925307A (en) | A kind of isoflavones and sodium hyaluronate pharmaceutical composition and its application | |
| CN109125318B (en) | Application of butylphthalide in preparation of medicine for treating xerophthalmia | |
| CN102988278A (en) | Bromfenac sodium hydrate eye drops and preparation method thereof | |
| CN102526112B (en) | Sustained-release pearl clear-sighted eye drops and preparation method thereof | |
| CN101579403A (en) | Ready-to-use Dactylicapnos scandens ophthalmic gel | |
| CN101579358A (en) | Ready-to-use traditional Chinese medicine ophthalmic gel | |
| CN110200904A (en) | A kind of drop intraocular pressure sustained release eye drop composition and preparation method thereof | |
| CN1954855B (en) | Eye preparation containing sodium hyaluronate for treating fundus macular degeneration and its preparation method | |
| CN108904510A (en) | Dexamethasone is used to inhibit or treat the purposes of cancer of pancreas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 215000 Dongyan Road, Loufeng East District, Suzhou Industrial Park, Jiangsu Province Patentee after: Suzhou Lezhu Pharmaceutical Co.,Ltd. Country or region after: China Address before: 215006 No. 666 South Garden Road, Suzhou Industrial Park, Jiangsu, China Patentee before: SUZHOU INDUSTRIAL PARK TIAN LONG MEDICAL Co.,Ltd. Country or region before: China |
|
| CP03 | Change of name, title or address | ||
| CX01 | Expiry of patent term |
Granted publication date: 20070815 |
|
| CX01 | Expiry of patent term |